The University of Cape Town (UCT) in South Africa has received funding to create a clinical study site to test compounds that can be developed into drug candidates for malaria and tuberculosis.
The US-based Novartis Institutes for Biomedical Research is providing the undisclosed amount of funding to the university to establish the site at its Cape Town-based Drug Discovery and Development Center (H3-D).
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.